Lyophilized Injectable Drugs Market Size By Drug (Anti-infective, Anti-neoplastic, Anticoagulant, Hormones, Antiarrhythmic), By Indication (Autoimmune Diseases, Respiratory Diseases, Gastrointestinal Disorders, Oncology, Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders), By Delivery (Prefilled Diluent Syringes, Multi-step Devices), By Packaging (Vials, Cartridges, Prefilled Devices), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 – 2030

Industry Overview

Lyophilized Injectable Drugs Market size was worth more than USD 250 billion in 2021 and is anticipated to witness over 13% CAGR from 2022-2030. Increasing prevalence of chronic diseases worldwide will foster industry growth.
 

Get more details on this report - Request Free Sample PDF
 

Surging prevalence of chronic diseases is a major factor accelerating the demand for these drugs. Owing to a growing sedentary lifestyle and rising consumption of processed foods, the prevalence of cardiovascular diseases, kidney disorders, cancer, and diabetes has seen considerable progress over the last decade. Additionally, the adoption of unhealthy lifestyle habits such as alcohol consumption and tobacco smoking has raised concerns about early chronic conditions in younger adults.
 

Several cases of product recalls of complex drugs may impede the growth of the lyophilized injectable drugs industry. In recent years, a substantial number of recalls have been reported by manufacturers due to the presence of unwanted foreign substances or adverse effects of drugs. Recalls have the potential to disrupt not only the company’s brand image but also alter the revenue performance.
 

Increasing cancer cases to boost market demand

Get more details on this report - Request Free Sample PDF
 

Lyophilized injectable drugs market from anti-neoplastic segment is projected to exhibit over 13% CAGR between 2022-2030. The substantial rise in demand for these medicines is due to their growing use as oncology drugs to address the surging incidences of cancer. Lyophilized anti-neoplastic drugs are also referred to as anticancer, chemo, chemotherapy, or cytotoxic drugs.
 

High prevalence of autoimmune disorders leads to development of key lyophilized drugs

Get more details on this report - Request Free Sample PDF
 

Autoimmune diseases are anticipated to account for more than 15% share of the lyophilized injectable drugs industry by 2030. Autoimmune disorders such as rheumatoid arthritis (RA), multiple sclerosis, type 1 diabetes, psoriatic arthritis, and celiac disease affect a significant number of individuals worldwide. Meanwhile, the American Autoimmune Related Diseases Association (AARDA) estimates that over 50 million people in the U.S. have at least one autoimmune condition, indicating the need for suitable lyophilized injectable drugs.
 

Advanced capabilities of prefilled devices with lyophilized injectable drugs enable improved care

Get more details on this report - Request Free Sample PDF
 

Lyophilized injectable drugs market from prefilled device segment is estimated to reach USD 210 billion by 2030. Prefilled devices are gaining popularity as they can help shorten waiting times for patients during hospital visits and improve the overall quality of care. It also ensures high accuracy drug dosing along with safe and convenient delivery of treatment. Even though there are several variations in the introduction of prefilled devices across a spectrum of drug classes and therapeutic categories, the product is expected to witness continuous demand.
 

Consistent dependence of patients on retail pharmacies for personalized medical products

Get more details on this report - Request Free Sample PDF
 

Lyophilized injectable drugs market from retail pharmacy segment is estimated to hold over 30% business share by 2030. Retail pharmacies have emerged as one of the key distribution channels as they offer easy access, affordable prices, high-end customer service, and a substantial variety of daily necessities products. In addition to this, retail outlets for drugs provide personalized advice for patients catering to their unique healthcare needs and concerns. In recent years, the number of retail pharmacies and pharmacy chains has grown considerably, indicating high consumer inclination toward this distribution channel.
 

Continuous rise in geriatric population to fuel Europe industry size

Get more details on this report - Request Free Sample PDF
 

Europe lyophilized injectable drugs market size is anticipated to surpass USD 185 billion by 2030. The region is expected to emerge as a lucrative landscape for industry expansion, with the rising prevalence of cancer and other health conditions. Europe is home to some of the largest elderly populations in the world. The rising geriatric population, lacking a robust immune and metabolic system that increases the risk of terminal illnesses, will also be a key industry driver. Studies have found that Belgium, Netherlands, Denmark, and Irelands have the highest rate of cancer patients in Europe among other native countries.
 

New product launches to strengthen industry development

Some of the leading lyophilized injectable drugs manufacturers worldwide are Bristol Myers Squibb, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Sanofi, Aurobindo Pharmaceuticals, Fresenius SE & Co. KGaA (Fresenius Kabi), Merck & Co., Inc, Zydus Group, Vetter Pharma, Johnson & Johnson Services, Inc, Takeda Pharmaceutical Company Limited, and Cipla Ltd. These companies are focusing on the development of advanced and innovative devices that are affordable and user-friendly.
 

Impact of COVID-19 on the lyophilized injectable drugs market trends

The COVID-19 pandemic elevated the demand for critical therapeutics and drugs. The unprecedented crisis substantially accelerated the death rate globally and therefore resulted in immense pressure on the healthcare and pharmaceutical sectors to address the growing concerns. While the pandemic caused various disruptions to the supply chain and introduced new challenges for the industry, there was rapid surge in hospitalization rate and growing demand for vaccine. Furthermore, as vaccine manufacturers ramped up production, the need for optimum storage conditions for liquid drugs gained momentum.
 

The lyophilized injectable drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2030, for the following segments:

By Drug

• Anti-infective
• Anti-neoplastic
• Anticoagulant
• Hormones
• Antiarrhythmic
• Others

By Indication

• Autoimmune diseases
• Respiratory diseases
• Gastrointestinal disorders
• Oncology
• Cardiovascular diseases
• Infectious diseases
• Metabolic disorders
• Others

By Delivery

• Prefilled diluent syringes
• Multi-step devices

By Packaging

• Vials
• Cartridges
• Prefilled devices

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Belgium
  • Netherlands
  • Norway
  • Switzerland
  • Others
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • New Zealand
  • Singapore
  • Thailand
  • Others
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
  • Others
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Iran
  • Others